Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 36 |
| Active Pipeline (Recruiting Now) | 19 (7) |
| Completed vs Stopped Early | 13 / 4 (11.1%) |
| Median Closed Actual Enrollment | 80 participants |
| Physical Hospital Site Disclosure | 99.8% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 5 (3 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario Vall d'Hebron | Barcelona | 7 |
| Hospital Universitario La Paz | Madrid | 6 |
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07387549 | A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Phase III | RECRUITING |
| NCT06016842 | A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase III | RECRUITING |
| NCT06937931 | A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | Phase II | RECRUITING |
| NCT04526665 | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | Phase III | ACTIVE NOT RECRUITING |
| NCT05627362 | A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Ipsen Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.